Impact of Intravenous Iron Repletion On Mechanisms of Exercise InTolerance in HFpEF (IRONMET-HFpEF)
Status:
Not yet recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine if the correction of functional iron
deficiency by administering a single dose of intravenous iron (ferric derimaltose or
Monoferric®) in participants with heart failure with preserved ejection fraction (HFpEF) will
improve exercise capacity as measured by the change in peak oxygen uptake (peak VO2) from
baseline to 12 weeks.
Phase:
Phase 4
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI) National Institutes of Health (NIH) Pharmacosmos A/S